Phase 1 Study of 89Zr-DFO-HuMab-5B1 (MVT-2163) With HuMab-5B1 (MVT-5873) in Patients With Pancreatic Cancer or Other CA19-9 Positive Malignancies

Trial Profile

Phase 1 Study of 89Zr-DFO-HuMab-5B1 (MVT-2163) With HuMab-5B1 (MVT-5873) in Patients With Pancreatic Cancer or Other CA19-9 Positive Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Zirconium 89 5B1 (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Diagnostic use; First in man; Pharmacokinetics
  • Sponsors MabVax Therapeutics
  • Most Recent Events

    • 14 Jun 2017 According to a MabVax Therapeutics media release, to date, twelve patients have been treated in this first-in-human trial.
    • 14 Jun 2017 According to a MabVax Therapeutics media release, data from the study were presented in a poster session and podium talk at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2017.
    • 14 Jun 2017 Results published in a MabVax Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top